Drilldown: Medicines
Use the filters below to narrow your results.
generic:
None (1) ·
Amantadine (1) ·
Apomorphine (1) ·
Asenapine (1) ·
Benztropine (1) ·
Biperiden (1) ·
Bromocriptine (1) ·
Cabergoline (1) ·
Carbidopa/levodopa (1) ·
Chlorpromazine (1) ·
Clozapine (1) ·
Droperidol (1) ·
Entacapone (1) ·
Fluphenazine (1) ·
Iloperidone (1) ·
Levodopa (1) ·
Loxapine (1) ·
Lurasidone (1) ·
Molindone (1) ·
Opicapone (1) ·
Paliperidone (1) ·
Perphenazine (1) ·
Pimozide (1) ·
Rasagiline (1) ·
Rotigotine (1) ·
Safinamide (1) ·
Selegiline (1) ·
Thioridazine (1) ·
Thiothixene (1) ·
Tolcapone (1) ·
Trifluoperazine (1) ·
Trihexyphenidyl (1) ·
Ziprasidone (1)
brand:
None (1) ·
Akineton (1) ·
Apokyn (1) ·
Artane (1) ·
Azilect (1) ·
Clozaril (1) ·
Cogentin (1) ·
Comtan (1) ·
Dostinex (1) ·
Eldepryl (1) ·
Fanapt (1) ·
Geodon (1) ·
Inapsine (1) ·
Invega (1) ·
Latuda (1) ·
Loxitane (1) ·
Mellaril (1) ·
Moban (1) ·
Navane (1) ·
Neupro (1) ·
Ongentys (1) ·
Orap (1) ·
Parlodel (1) ·
Prolixin (1) ·
Rexulti (1) ·
Saphris (1) ·
Sinemet (1) ·
Stelazine (1) ·
Symmetrel (1) ·
Tasmar (1) ·
Thorazine (1) ·
Trilafon (1) ·
Xadago (1)
classes: (Click arrow to add another value)
mechanism:
Butyrophenone D2 antagonist (1) ·
Central and peripheral COMT inhibitor (1) ·
D1/D2/D3 receptor agonist (1) ·
D2 agonist; D1 partial agonist (1) ·
D2 receptor agonist (1) ·
D2 receptor antagonist; also H1, alpha-1, muscarinic antagonist (1) ·
D2/5-HT2A antagonist (1) ·
D2/5-HT2A antagonist; 5-HT7 antagonist (1) ·
D2/5-HT2A antagonist; active metabolite of risperidone (1) ·
D2/5-HT2A antagonist; SRI and NRI (1) ·
Dibenzoxazepine D2/5-HT2 antagonist (1) ·
Dihydroindolone D2 antagonist (1) ·
Diphenylbutylpiperidine D2 antagonist (1) ·
Dopamine precursor (1) ·
Dopamine precursor + DOPA decarboxylase inhibitor (1) ·
Irreversible selective MAO-B inhibitor (2) ·
MAO-B inhibitor; sodium channel blocker; glutamate release inhibitor (1) ·
Multi-receptor antagonist (D2, 5-HT2A, H1, alpha) (1) ·
Multi-receptor antagonist; low D2 affinity (1) ·
Muscarinic receptor antagonist (1) ·
Muscarinic receptor antagonist; dopamine reuptake inhibitor (1) ·
NMDA antagonist; dopamine releasing agent (1) ·
Non-selective dopamine receptor agonist (1) ·
Once-daily COMT inhibitor (1) ·
Partial agonist at D2 and 5HT1A. Antagonist at 5HT2A, α1A, α1B, α2C. More potent 5HT2A antagonism, 5HT1A partial agonism, and α1 antagonism (relative to D2 partial agonism) than aripiprazole, proposed to reduce akathisia and enhance affective/cognitive effects. (1) ·
Peripheral COMT inhibitor (1) ·
Phenothiazine D2 antagonist (4) ·
Selective M1 muscarinic antagonist (1) ·
Thioxanthene D2 antagonist (1)
uses:
None (32) ·
Schizophrenia (FDA-approved 2015). Adjunctive treatment of major depressive disorder (2015). '''Agitation associated with dementia due to Alzheimer disease''' (FDA-approved May 2023, first agent specifically approved for this problem). Investigational for PTSD (combined with sertraline). (1)
starting dose:
preparations:
duration:
halflife:
Showing below up to 33 results in range #1 to #33.